Showing results (2151-2160 of 2,448) with videos related to

Sort By:
Pageof 245
Clinical and Translational Gastroenterology|August 1, 2021
The Sulfur Microbial Diet and Risk of Colorectal Cancer by Molecular Subtypes and Intratumoral Microbial Species in Adult MenDaniel R Sikavi, Long H Nguyen, Koichiro Haruki, et al.
Cancer|January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMsAaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
Current Psychology (New Brunswick, N.J.)|May 23, 2022
Impact of restrictive COVID-19 measures on daily momentary affect in an epidemiological youth sample in Hong Kong: An experience sampling studyStephanie M Y Wong, Yandy Y Li, Christy L M Hui, et al.
Elife|December 21, 2023
Identifying metabolic features of colorectal cancer liability using Mendelian randomizationCaroline Bull, Emma Hazelwood, Joshua A Bell, et al.
Cancer Epidemiology|July 25, 2016
Common variants in the obesity-associated genes FTO and MC4R are not associated with risk of colorectal cancerBaiyu Yang, Aaron P Thrift, Jane C Figueiredo, et al.
British Journal of Cancer|November 23, 2024
Associations of blood lipids and LDL cholesterol lowering drug-targets with colorectal cancer risk: a Mendelian randomisation studyWing Ching Chan, Lili Liu, Emmanouil Bouras, et al.
JAMA Cardiology|October 15, 2025
Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of AspirinZoe K McQuilten, Le T P Thao, Alexander G Bick, et al.
Nature|February 15, 2019
Sleep modulates haematopoiesis and protects against atherosclerosisCameron S McAlpine, Máté G Kiss, Sara Rattik, et al.
Cancer Immunology, Immunotherapy : CII|September 16, 2021
Immune cell profiles in the tumor microenvironment of early-onset, intermediate-onset, and later-onset colorectal cancerTomotaka Ugai, Juha P Väyrynen, Mai Chan Lau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2001
Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trialA M Scott, F T Lee, W Hopkins, et al.
Pageof 245